Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-19T12:00:53.510Z Has data issue: false hasContentIssue false
  • English
  • Français

Ondansetron disintegrating tablets of 8 mg twice a day for 3 days did not reduce the incidence of nausea or vomiting after laparoscopic surgery

Published online by Cambridge University Press:  02 June 2005

K. S. Thagaard ,
S. Steine  and
J. Raeder
K. S. Thagaard
Affiliation:
Ullevaal University Hospital, Department of Anaesthesia, Oslo, Norway
S. Steine
Affiliation:
Ullevaal University Hospital, Department of General Practice Medicine, Oslo, Norway
J. Raeder
Affiliation:
Ullevaal University Hospital, Department of Anaesthesia, Oslo, Norway
Get access

Abstract

Summary

Background and objective: Although many antiemetic drugs are available for intravenous use in the hospital setting, few are available after patient discharge. Consequently, nausea and vomiting are frequent complaints from patients at home after ambulatory surgery. We tested the hypothesis that the new 8 mg ondansetron disintegrating tablets will decrease the rate of nausea and vomiting at home after laparoscopic surgery.

Methods: Ninety-six patients were studied in a randomized double-blind study. Starting the first evening after operation and continuing every 12 h for 3 days, patients received either placebo or ondansetron 8 mg disintegrating tablets orally. The patients returned a questionnaire about postoperative nausea and vomiting, other side-effects, e.g. dizziness, headache, nightmare, anxiety and pain, as well as their overall satisfaction at 24 and 72 h after completion of surgery.

Results: The rates of nausea and vomiting were similar in the two groups, both during the first 24 h (28 versus 48%, placebo and ondansetron, respectively (ns) and during the 24–72 h (21 versus 35% (ns)). The incidence rate of vomiting was 8% (placebo) versus 12% (ondansetron) during the first 24 h (ns) and 9 versus 13% respectively in the 24–72 h (ns). No difference between groups was observed in overall satisfaction, incidence of postoperative pain or other side-effects.

Conclusions: The use of ondansetron disintegrating tablets of 8 mg twice a day for 3 days did not reduce the incidence of nausea and vomiting in patients undergoing outpatient laparoscopic surgery.

Keywords

ANALGESIAANTIEMETICS, ondansetronENDOSCOPY, laparoscopyPAIN, pain, postoperative, POSTOPERATIVE COMPLICATIONS, postoperative nausea and vomiting
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 20 , Issue 2 , February 2003 , pp. 153 - 157
Copyright
2003 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Raeder JC, Mjaland O, Aasbo V, Grogaard B, Buanes T. Desflurane versus propofol maintenance for outpatient laparoscopic cholecystectomy. Acta Anaesthesiol Scand 1998; 42: 106–110.Google Scholar
Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose–response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997; 87: 1277–1289.Google Scholar
VanDenBerg CM, Kazmi Y, Stewart J, et al. Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion. Am J Health Syst Pharm 2000; 57: 1046–1050.Google Scholar
Jann MW, ZumBrunnen TL, Tenjarla SN, Ward ES Jr, Weidler DJ. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy 1998; 18: 288–294.Google Scholar
Davidson N, Rapoport B, Erikstein B, et al. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. Clin Ther 1999; 21: 492–502.Google Scholar
LeBourgeois JP, McKenna CJ, Coster B, et al. Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment. Clin Oncol (R Coll Radiol) 1999; 11: 340–347.Google Scholar
Gan TJ, Franiak R, Reeves J, Hartle AJ. Ondansetron disintegrating tablets (ODT) reduces post-discharge emesis and increases patient satisfaction. In: Abstracts of the Annual Scientific Meeting, 2000.Park Ridge, USA: American Society of Anesthesiologists, 2000: A-34.
Apfel CC, Greim CA, Haubitz I, et al. A risk score to predict the probability of postoperative vomiting in adults. Acta Anaesthesiol Scand 1998; 42: 495–501.Google Scholar
Bowhay AR, May HA, Rudnicka AR, Booker PD. A randomized controlled trial of the antiemetic effect of three doses of ondansetron after strabismus surgery in children. Paediatr Anaesth 2001; 11: 215–221.Google Scholar
Pearman MH. Single dose intravenous ondansetron in the prevention of postoperative nausea and vomiting. Anaesthesia 1994; 49 (Suppl): 11–15.Google Scholar